Methylenedioxybenzylamphetamine

Methylenedioxybenzylamphetamine

Names
IUPAC name 1-(1,3-benzodioxol-5-yl)-N-benzylpropan-2-amine
Identifiers
CAS Number	65033-29-6
3D model (JSmol)	Interactive image
ChemSpider	15110233
PubChem CID	20507314
UNII	QR8242661A
CompTox Dashboard (EPA)	DTXSID10608233
InChI InChI=1S/C17H19NO2/c1-13(18-11-14-5-3-2-4-6-14)9-15-7-8-16-17(10-15)20-12-19-16/h2-8,10,13,18H,9,11-12H2,1H3 Key: DWLUHTUYTBWOLO-UHFFFAOYSA-N
SMILES C1=C3C(=CC=C1CC(C)NCC2=CC=CC=C2)OCO3
Properties
Chemical formula	C17H19NO2
Molar mass	269.343 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

MDBZ, or 3,4-methylenedioxy-N-benzylamphetamine, is a lesser-known psychedelic drug. It is the N-benzyl derivative of MDA. MDBZ was first synthesized by Alexander Shulgin. In his book PiHKAL (Phenethylamines i Have Known And Loved), the minimum dosage is listed as 150 mg, and the duration unknown. MDBZ produces few to no effects. Very few data exist about the pharmacological properties, metabolism, and toxicity of MDBZ.

In an episode of the British spoof documentary TV show Brass Eye, David Amess MP was fooled into recording a warning against a fictitious new drug called "cake". When asked a parliamentary question about it, the Home Office incorrectly assumed Amess was referring to 3,4-methylenedioxy-N-benzylamphetamine.^[1]

Legality

United Kingdom

This substance is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act.^[2]

See also

• Phenethylamine
• Psychedelics, dissociatives and deliriants
• MDA

References

External links

• MDBZ entry in PiHKAL
• MDBZ entry in PiHKAL • info